Viewing Study NCT01445535

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 10:04 PM
Ignite Modification Date: 2026-02-25 @ 7:03 PM
Study NCT ID: NCT01445535
Status: COMPLETED
Last Update Posted: 2021-11-03
First Post: 2011-09-30
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None T-Cell Peripheral Lymphoma View
None Gamma Delta Hepatosplenic T-Cell Lymphoma View
None Subcutaneous Panniculitis-Like T-Cell Lymphoma View
None NK T-Cell Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CD2 Positive View
None Toxicity View
None EBV Lymphoma View
None Chemotherapy Naive View
None Maximum Tolerated Dose View
None Lymphoma View
None T-Cell Lymphoma View
None NK T-Cell Lymphoma View